Ackman funds $400M institute after daughter's experimental eye treatment fails

Key points

• Lucy Ackman collapsed in February 2026 with a brain hemorrhage, losing the ability to move, speak, or see.
• Doctors at Mount Sinai Hospital performed a first-of-its-kind procedure, transferring mitochondria from her leg muscles to her eyes.
• The treatment initially allowed Lucy to detect light, but the effect disappeared after approximately one month.
• Ackman announced plans to invest more than $400 million in a new research institute for brain science, rehabilitation, and aging.
• The FDA approved the procedure under an expanded access pathway for urgent, unapproved treatments.

Background

This medical crisis follows a period of significant portfolio activity for Ackman. In August 2026, he overhauled Pershing Square's holdings, adding stakes in Netflix, Visa, and Mastercard, and exited a Universal Music Group position. He also publicly criticized New York City's proposed rent freeze policies in early August, arguing they would harm the local business climate.

How outlets are covering it

The Washington Post and Yahoo News emphasize the personal nature of the decision and the 'amazing potential' of the therapy, despite its current failure. The Korean outlet Maeil Kyungje highlights the scientific uncertainty, noting that while animal studies in Nature showed promise, the human trial's short-term success did not translate to long-term recovery. Benzinga provided no substantive reporting on the story, focusing instead on technical site data.

Why it matters

This case highlights the ethical and scientific boundaries of 'compassionate use' in medicine. It demonstrates how wealthy individuals can access unapproved, high-risk experimental treatments through FDA pathways, raising questions about equity in access to cutting-edge, unproven medical interventions.

What to watch

Ackman's new research institute will likely focus on understanding why the mitochondrial transplant failed to provide lasting results. The scientific community will monitor whether future trials can achieve sustained nerve function recovery, potentially leading to new standards for treating optic nerve damage.